Company: IMCR
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001671927-25-000006
Chunk: 21

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 21
---
-7

Table of Contents

Immunocore Holdings Plc

Consolidated Statements of Cash Flows

(in thousands)Year Ended December 31,202420232022Cash flows from operating activitiesNet loss$(51,087)$(55,287)$(52,543)Adjustments for:Share-based compensation expense34,190 32,469 32,888 Depreciation4,204 4,090 5,335 Unrealized foreign exchange losses (gains)599 13,827 (14,482)Unrealized gains on marketable securities(14,577)— — Loss on loan extinguishment3,853 — 1,686 Non-cash lease expense1,912 1,647 2,076 Other1,838 412 (4)Changes in assets and liabilities:Increase in accounts receivable(12,348)(17,871)(26,264)(Increase) decrease in prepayments and other current assets(11,600)8,544 (14,694)Increase in accounts payable7,272 2,625 4,913 Increase in accrued expenses71,502 39,088 41,757 Decrease in deferred revenue(1)(8,013)(25,504)Decrease in operating lease liabilities(1,648)(2,226)(1,782)Increase in other operating assets(8,048)(15,012)(4,729)(Decrease) increase in other operating liabilities— (1,353)2,138 Net cash provided by (used in) operating activities26,061 2,940 (49,209)Cash flows from investing activitiesProceeds from sale of property, plant and equipment44 — 6 Purchase of marketable securities(350,000)— — Purchase of property, plant and equipment(5,173)(5,425)(2,203)Net cash used in investing activities(355,129)(5,425)(2,197)Cash flows from financing activitiesProceeds from issue of ordinary shares, net— — 139,515 Exercise of share options6,800 34,346 9,696 Loan repayments(50,000)— (50,000)Debt prepayments and extinguishments(2,061)— (2,000)Non-current interest-bearing loan received402,500 — 50,000 Debt issuance payments(